Orforglipron Weight Loss: What the Trials Show So Far
The biggest average Weight loss in orforglipron trials: 11.1% on Foundayo 17.2 mg daily in ATTAIN-1, against 2.1% on placebo.
- Major trials here
- 3
- Top average loss
- 11.1%
- Placebo, same trial
- 2.1%
- Biggest A1C drop
- 1.48 points
Foundayo in brief
Half-life ranges from 29 to 49 hours. After 39 h, half remains, while five half-lives leave about 3% (8.1 d).
Over 72 weeks in ATTAIN-1, the result was 11.1% of body weight, versus 2.1% with placebo.
Monthly prices in US dollars, covering list price and self-pay offers, each taken from the maker's price page.
Sources: FDA label (DailyMed), Eli Lilly, pricinginfo.lilly.com.
Every trial in one table
The trial name links to its ClinicalTrials.gov record.
| Trial | Who was in it | People | Weeks | Compared with | Main result | In the label as | NCT number |
|---|---|---|---|---|---|---|---|
| ATTAIN-1 | Adults with obesity or overweight, without diabetes | 3,127 | 72 | placebo | 11.1% weight lost | Trial 1 in the Foundayo label | NCT05869903 |
| ATTAIN-2 | Adults with obesity or overweight who also have type 2 diabetes | 1,613 | 72 | placebo | 9.6% weight lost | Trial 2 in the Foundayo label | NCT05872620 |
| ACHIEVE-1 | Adults with early type 2 diabetes treated through diet and exercise alone | 559 | 40 | placebo | A1C 1.48 points lower | Not listed | NCT05971940 |
Weight loss in orforglipron trials
This is the average share of body weight that participants had lost by the end of each trial. Each trial enrolled a different group of people, so compare doses within a single trial first.
| Trial | Dose group | Average weight lost | Placebo or comparison | Weeks | Who was in it |
|---|---|---|---|---|---|
| ATTAIN-1 | Foundayo 5.5 mg daily | 7.4% | 2.1% | 72 | Adults with obesity or overweight, without diabetes |
| ATTAIN-1 | Foundayo 9 mg daily | 8.3% | 2.1% | 72 | Adults with obesity or overweight, without diabetes |
| ATTAIN-1 | Foundayo 17.2 mg daily | 11.1% | 2.1% | 72 | Adults with obesity or overweight, without diabetes |
| ATTAIN-2 | Foundayo 5.5 mg daily | 5.1% | 2.5% | 72 | Adults with obesity or overweight who also have type 2 diabetes |
| ATTAIN-2 | Foundayo 9 mg daily | 7% | 2.5% | 72 | Adults with obesity or overweight who also have type 2 diabetes |
| ATTAIN-2 | Foundayo 17.2 mg daily | 9.6% | 2.5% | 72 | Adults with obesity or overweight who also have type 2 diabetes |
Source: ATTAIN-1 (FDA label (DailyMed)).
A1C results in the orforglipron diabetes trials
| Trial | Dose group | A1C change | Placebo or comparison | Weeks | Who was in it |
|---|---|---|---|---|---|
| ACHIEVE-1 | Orforglipron 3 mg daily (publication dose name) | 1.24 points lower | 0.41 points lower | 40 | Adults with early type 2 diabetes treated through diet and exercise alone |
| ACHIEVE-1 | Orforglipron 12 mg daily (publication dose name) | 1.47 points lower | 0.41 points lower | 40 | Adults with early type 2 diabetes treated through diet and exercise alone |
| ACHIEVE-1 | Orforglipron 36 mg daily (publication dose name) | 1.48 points lower | 0.41 points lower | 40 | Adults with early type 2 diabetes treated through diet and exercise alone |
Source: ACHIEVE-1 (PubMed).
Safety signals
The Foundayo label warns of the following serious risks:
- A boxed warning for Thyroid C-cell tumors. In rodents, it caused thyroid C-cell tumors; whether it does so in people is unknown. It should not be used by anyone with a personal or family history of medullary thyroid cancer (MTC), or who has MEN 2.
- Pancreatic inflammation It can cause the pancreas to become inflamed. Stop it and get care when you have severe stomach pain that will not go away. Sometimes it spreads to your back.
- Severe stomach and gut reactions Stomach and gut side effects are common. People with severe gastroparesis are not advised to use it.
- Losing fluid can lead to kidney injury. Fluid loss from vomiting or diarrhea may lead to kidney injury. Tell someone about heavy fluid loss, and drink fluids.
- Low blood sugar Using it with insulin or a sulfonylurea raises the chance of low blood sugar, and those doses may need to be lowered.
- Serious allergic reactions Reports describe serious allergic reactions, including swelling of the face, lips or throat. Stop the medicine and get help immediately if this happens.
Source: FDA label (DailyMed).
Source: FDA label (DailyMed).
Trials of orforglipron recruiting now
Use ClinicalTrials.gov to find recruiting orforglipron trials. Once your state filter is set, speak with the study team to discuss costs and travel.